Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer

被引：0
|
作者：
S. Leppä
T. Saarto
L. Vehmanen
C. Blomqvist
I. Elomaa
机构：
[1] Helsinki University Central Hospital,Department of Oncology
[2] University of Helsinki,Molecular Cancer Biology Research Program, Biomedicum Helsinki
[3] University of Uppsala,Department of Oncolgy
来源：
Breast Cancer Research and Treatment | 2005年 / 90卷
关键词：
adjuvant; bisphosphonate; breast cancer; matrix metalloproteinase; prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Purpose. Serum postoperative matrix metalloproteinase 2 (MMP-2) level is a predictor of outcome in node positive breast cancer and can be used to stratify patients into low and high risk groups. Our aim was to determine how clodronate treatment influences MMP-2 associated clinical outcome.
引用
收藏
页码：117 / 125
页数：8
相关论文
共 50 条
  • [21] Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma
    Mönig, SP
    Baldus, SE
    Hennecken, JK
    Spiecker, DB
    Grass, G
    Schneider, PM
    Thiele, J
    Dienes, HP
    Hölscher, AH
    HISTOPATHOLOGY, 2001, 39 (06) : 597 - 602
  • [22] Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype
    Fabienne Grieu
    Wei Qi Li
    Barry Iacopetta
    Breast Cancer Research and Treatment, 2004, 88 : 197 - 204
  • [23] Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype
    Grieu, F
    Li, WQ
    Iacopetta, B
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 (03) : 197 - 204
  • [24] Outcome analysis of patients with breast cancer and positive sentinel node
    Syed, A.
    Eleti, S. R.
    Buhain, R.
    ANNALS OF ONCOLOGY, 2015, 26
  • [25] Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
    A Talvensaari-Mattila
    P Pääkkö
    T Turpeenniemi-Hujanen
    British Journal of Cancer, 2003, 89 : 1270 - 1275
  • [26] Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma
    Talvensaari-Mattila, A
    Pääkkö, P
    Turpeenniemi-Hujanen, T
    BRITISH JOURNAL OF CANCER, 2003, 89 (07) : 1270 - 1275
  • [27] MMP-2 but not MMP-9 associated with COX-2 and survival in gastric cancer
    Mrena, J.
    Wiksten, J-P
    Nordling, S.
    Kokkola, A.
    Ristimäki, A.
    Haglund, C.
    JOURNAL OF CLINICAL PATHOLOGY, 2006, 59 (06) : 618 - 623
  • [28] Expression of Metalloproteinases MMP-2 and MMP-9 in Sentinel Lymph Node and Serum of Patients with Metastatic and Non-Metastatic Breast Cancer
    Daniele, A.
    Zito, A. F.
    Giannelli, G.
    Divella, R.
    Asselti, M.
    Mazzocca, A.
    Paradiso, A.
    Quaranta, M.
    ANTICANCER RESEARCH, 2010, 30 (09) : 3521 - 3527
  • [29] MMP-2 and MMP-9 gene polymorphisms associated with cervical cancer risk
    Zhang, Haiyan
    Li, Guang
    Zhang, Zhen
    Wang, Surong
    Zhang, Shiqian
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (12): : 11760 - 11765
  • [30] Treatment of sentinel node-positive breast cancer
    Chagpar, Anees B.
    McMasters, Kelly M.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (08) : 1233 - 1239
12345